— 01 · At a Glance
What is Alpha PRRT?
★ In one paragraph
Alpha PRRT uses the same DOTATATE peptide that binds somatostatin-2 receptors on neuroendocrine tumour cells — but pairs it with actinium-225, an alpha emitter, in place of the beta emitter lutetium-177. The alpha payload delivers far denser radiation over a much shorter tissue range, producing potent cell killing including against Lu-resistant tumour clones. Alpha PRRT is primarily a salvage line for patients whose NETs have progressed on standard Lu-177 DOTATATE.
The therapy is administered as an outpatient intravenous infusion every 8 to 12 weeks for 3 to 4 cycles. Each cycle is preceded by amino acid renal protection to reduce kidney radiation exposure. The total course typically spans 8 to 10 months. Like beta PRRT, eligibility starts with a 68Ga-DOTATATE PET/CT confirming strong SSTR-2 expression in the disease.
Alpha PRRT is an established but still-emerging radioligand therapy — offered worldwide at specialist theranostic centres including the original Heidelberg group, AIIMS Delhi, our department at FMRI, and a handful of others. It is delivered on a clinical compassionate use basis, with case-by-case multidisciplinary review.
— 02 · Mechanism
Why alpha works when beta no longer does.
The fundamental difference between Lu-177 and Ac-225 lies in the physics of the radiation each emits, not in the targeting molecule. DOTATATE binds SSTR-2 the same way in both. What changes is what happens after binding:
- Beta particles (Lu-177) travel approximately 2 millimetres through tissue and deliver moderate energy per micrometre. Excellent for moderate-sized disease, less effective against very small tumour foci or resistant clones.
- Alpha particles (Ac-225) travel only 50 to 100 micrometres — about the diameter of 2 to 5 cells — but with ~100 times higher linear energy transfer (LET) than beta. Each alpha strike produces dense, clustered DNA damage that the cell cannot repair.
- Repair-independent. Lu-resistant cancer cells often resist beta because their DNA repair machinery has adapted. Alpha damage overwhelms repair pathways — making it effective even in beta-refractory disease.
Ac-225 itself decays through a chain of four daughter alphas, multiplying the cytotoxic dose delivered per molecule bound. This is why 100 kBq/kg of Ac-225 produces tumour effect comparable to gigabecquerel doses of Lu-177 — despite vastly lower administered activity.
— 03 · Side by Side
Lu-177 DOTATATE vs Ac-225 DOTATATE.
The same peptide. Different radiation. Different roles in the treatment pathway.
Beta · First line
Lu-177 DOTATATE
The standard PRRT for SSTR-positive NETs. Approved internationally (Lutathera), reimbursed by major insurers. Established efficacy by the NETTER-1 trial.
ParticleBeta · ~2 mm range
Half-life6.7 days
Dose / cycle7.4 GBq
Cycles4, every 8-12 weeks
RoleFirst-line PRRT
Alpha · Salvage
Ac-225 DOTATATE
High-LET alpha salvage after Lu-177 progression. Compassionate use at specialist centres. Effective against Lu-resistant clones via repair-independent damage.
ParticleAlpha · 50–100 μm range
Half-life10 days
Dose / cycle100 kBq/kg
Cycles3–4, every 8–12 weeks
RoleSalvage / refractory disease
— 04 · Switching Lines
When to switch from β to Alpha.
Most patients receive Alpha PRRT after a structured progression on standard PRRT. The clinical triggers we consider for switching:
- Radiographic progression on Lu-DOTATATE PRRT — documented growth or new lesions on interim or end-of-treatment 68Ga-DOTATATE PET, while SSTR-2 expression remains preserved.
- Biochemical progression — rising chromogranin A or other markers despite ongoing beta therapy.
- Symptomatic deterioration — recurrence or worsening of carcinoid syndrome, hormonal symptoms or tumour-mass effects.
- Aggressive baseline biology — in selected patients with very high SSTR-2 avidity but unfavorable prognostic features (high Ki-67, rapid initial growth, bulky disease), alpha may be offered earlier in the pathway as primary therapy after multidisciplinary review.
★ Tandem and sequential strategies
Some patients are not strictly "Lu-progressed" but partial responders — benefiting from beta but with residual or marginal disease. In these cases, our department considers tandem Lu+Ac therapy (alternating cycles) or planned sequential Lu→Ac escalation. The decision is made at multidisciplinary tumour board with the referring oncologist.
— 05 · Eligibility
Who is a candidate?
Alpha PRRT eligibility is determined case by case at our multidisciplinary tumour board. Standard criteria:
- Histologically confirmed neuroendocrine tumour — gastroenteropancreatic NET (GEP-NET), lung NET, malignant paraganglioma, metastatic carcinoid, or another SSTR-2-positive NET subtype.
- Progressive or refractory disease — either after Lu-177 DOTATATE PRRT or in highly aggressive baseline disease meeting alpha first-line criteria.
- Strong SSTR-2 expression on 68Ga-DOTATATE PET/CT — with uptake (SUVmax) substantially higher than physiological liver background. Patients with weak or heterogeneous SSTR-2 expression are unlikely to respond and we counsel against offering therapy.
- Adequate organ function: creatinine clearance > 50 mL/min, haemoglobin > 9 g/dL, platelets > 100 × 10⁹/L, AST/ALT < 3× upper limit.
- Life expectancy > 6 months and ECOG performance status 0–2.
- Multidisciplinary tumour board recommendation. Informed consent regarding the compassionate-use nature of Alpha PRRT.
— 06 · Protocol
The treatment cycle.
Each Alpha PRRT cycle is administered as an outpatient procedure with strict renal protection. The standard adult cycle:
01
Pre-treatment work-up
68Ga-DOTATATE PET/CT (mandatory). Recent CT or MRI of disease. Baseline bloods, renal function, liver function, chromogranin A. Multidisciplinary tumour board review. Discontinuation of long-acting somatostatin analogs 4–6 weeks before therapy.
02
Amino acid renal protection
IV infusion of lysine-arginine amino acid solution starting 60 minutes before therapy and continuing upto 24 hours. This blocks renal tubular reabsorption of DOTATATE and protects kidney function.
03
Therapy infusion · outpatient
Slow IV infusion of 100 kBq/kg Ac-225 DOTATATE over 10–20 minutes with continuous monitoring. Antiemetic premedication. Total day-of-therapy time approximately 6 hours including amino acid infusion.
04
Interim review · cycle 2 or 3
Clinical assessment, biochemistry, and 68Ga-DOTATATE PET imaging between cycles 2 and 3. Decision to continue, pause or modify protocol based on response, biomarker trends, and tolerability.
Total course duration: typically 8 to 10 months for a 3 to 4 cycle protocol. Each cycle is a day-care outpatient procedure; international patients typically combine each cycle with a 2 to 3 night stay in Gurugram.
— 07 · Evidence
What the data shows.
Alpha PRRT is supported by accumulating phase 1 and phase 2 evidence from Heidelberg (Kratochwil), AIIMS Delhi (Ballal, Yadav), Essen, Pretoria (Sathekge), and other major theranostic centres. Across published series:
60–85%
Disease control rate in Lu-refractory NETs
15–30%
Partial response (RECIST) after 3–4 cycles
~14 mo
Median PFS in salvage cohort series
Heidelberg first-in-human
Kratochwil and colleagues at Heidelberg1 reported the first clinical use of Ac-225 DOTATOC in 2014 in a small series of patients with progressive metastatic NETs — documenting response in 3 of 4 patients who had failed prior Lu-177 PRRT. The proof-of-concept established that alpha PRRT could induce response in beta-refractory disease.
AIIMS Indian cohort
Ballal, Yadav and colleagues at AIIMS Delhi2 reported the largest single-centre series of Ac-225 DOTATATE in 32 patients with progressive metastatic gastroenteropancreatic NETs. Disease control rate was 84.4 percent, with morphological response in 28 percent and biomarker response (chromogranin A decline) in 65 percent. The Indian series confirmed both safety and efficacy of Ac-225 DOTATATE in routine clinical practice.
Salvage cohorts internationally
Subsequent series from Demir (Turkey)3, Sathekge (South Africa)4, and others have built consistent salvage data: median progression-free survival around 12 to 14 months in heavily pre-treated Lu-refractory patients, with manageable toxicity profile and meaningful quality of life.
— 08 · Tolerability
Side effects.
Alpha PRRT tolerability overlaps with conventional Lu-DOTATATE PRRT but with some differences worth understanding before treatment:
Common (>15% of patients)
- Fatigue — mild to moderate, typically 1 to 2 weeks after each cycle.
- Mild nausea — usually controlled with pre-medication; less frequent than during chemotherapy.
- Cytopenia — reductions in haemoglobin, platelets, lymphocytes; more pronounced than with beta PRRT, with nadir at 4 to 6 weeks and recovery by 10 to 12 weeks.
- Mild xerostomia — dry mouth, less prominent than with Alpha PSMA because SSTR-2 expression in salivary glands is much lower than PSMA.
Uncommon (1–15%)
- Renal effects — mild creatinine rise; mitigated by amino acid protection.
- Hepatic dysfunction — in patients with extensive hepatic disease.
- Bone-marrow suppression requiring growth factor support — in heavily pre-treated patients.
Rare but serious
- Severe and prolonged cytopenia — particularly in patients with marrow disease.
- Late renal toxicity — rare with appropriate amino acid protection and inter-cycle creatinine monitoring.
- Secondary haematological malignancy — very rare; risk grows with cumulative radiation exposure.
— 09 · Pricing
Cost in India.
Indicative cycle pricing. Figures cover the radiopharmaceutical, infusion suite, amino acid renal protection, and standard monitoring. 68Ga-DOTATATE PET, additional imaging and inpatient stay billed separately.
| Variant |
Per cycle |
3–4 cycle course |
Ac-225 DOTATATE (adult, Indian) |
~ ₹ 13,00,000–16,00,000
~ USD 14,500–17,800 |
~ ₹ 40–60 L
~ USD 44,500–67,000 |
Ac-225 DOTATATE (international) |
~ ₹ 13,50,000–16,20,000
~ USD 15,000–18,000 |
~ ₹ 42–65 L
~ USD 46,700–72,200 |
Tandem Lu + Ac (combined) |
On request
case-by-case |
Individualised
based on protocol |
68Ga-DOTATATE PET (diagnostic) |
~ ₹ 25,000–30,000
~ USD 280–335 |
Single scan
plus interim review |
★ Please read
Figures are indicative ranges, not quotes, presented at 1 USD = ₹ 90. They cover therapy fees only and exclude FMRI hospital charges, concomitant medication, and inpatient stay.
Some major Indian insurers cover Alpha PRRT case-by-case for the approved compassionate use indications. WhatsApp us for a pre-authorisation pack.
— 10 · Availability
Next available Alpha PRRT slots.
Alpha PRRT at our centre is scheduled on alternate Fridays, governed by Ac-225 isotope availability and patient demand. Reservations require 7 days advance notice for radiopharmaceutical procurement.
Alpha PRRT calendar — next slots.
Frequently asked questions.
Alpha PRRT is peptide receptor radionuclide therapy using actinium-225 (an alpha emitter) chelated to DOTATATE, a somatostatin receptor (SSTR-2) ligand. Like conventional Lu-177 PRRT, the DOTATATE molecule binds SSTR-2 receptors on neuroendocrine tumour cells.
Unlike beta PRRT, the Ac-225 payload delivers alpha radiation — particles with approximately 100 times higher linear energy transfer (LET) than beta — causing dense, lethal DNA damage over a very short tissue range (about 50 to 100 micrometres). Alpha PRRT is principally used as salvage therapy after Lu-DOTATATE progression.
Alpha PRRT is most commonly considered after progression on Lu-177 DOTATATE PRRT (the standard beta-PRRT line). It is also occasionally offered as first-line for very aggressive NET disease with high SSTR-2 avidity but unfavourable prognostic features, where alpha may provide more durable response than beta.
Eligibility is confirmed on 68Ga-DOTATATE PET showing strong SSTR-2 expression and after multidisciplinary tumour-board review.
Localised low-grade NETs are often curable with complete surgical resection. Metastatic or high-grade NETs are typically not curable but are highly treatable — patients can live with their disease for many years using combination therapy including surgery, somatostatin analogs (octreotide / lanreotide), Lu-177 DOTATATE PRRT, Alpha PRRT (Ac-225 DOTATATE), liver-directed therapies, and chemotherapy.
Modern theranostic care has substantially improved survival for metastatic NET patients.
Both use the same DOTATATE peptide that binds SSTR-2 receptors on NET cells. The radionuclide is different: Lu-177 emits beta particles with a tissue range of approximately 2 millimetres, whereas Ac-225 emits alpha particles with a range of 50 to 100 micrometres.
Alpha radiation causes much denser DNA damage per unit distance, making it more potent against small disease foci and Lu-resistant clones. Lu-177 PRRT is the standard first line; Alpha PRRT is salvage.
There is no specific 'NET diet' that treats the disease, but symptomatic patients with carcinoid syndrome benefit from avoiding triggers that worsen serotonin-mediated symptoms — alcohol, aged cheeses, smoked or fermented foods, spicy meals, and large carbohydrate-rich meals.
Adequate protein intake supports general oncological wellbeing. Patients with significant diarrhoea require electrolyte and vitamin (particularly B3 / niacin) replacement. Detailed dietary guidance should come from a registered dietitian familiar with NET physiology.
Stage 4 (metastatic) neuroendocrine cancer is a serious diagnosis but the prognosis varies widely by tumour grade and treatment response. Well-differentiated low-grade (G1/G2) metastatic NETs commonly have median survival measured in years — often more than 10 years with active modern management.
High-grade neuroendocrine carcinomas (G3) have a more aggressive course. PRRT, Alpha PRRT, and somatostatin analogs have substantially extended survival for SSTR-positive metastatic disease.
NETs sit on a behavioural spectrum, but in modern WHO 2019/2022 classification virtually all NETs are considered to have malignant potential. Small, low-grade, localised NETs may behave indolently for many years and never metastasize — these are sometimes loosely called 'benign' clinically.
Technically they remain neoplasms that need lifelong follow-up. Truly benign equivalents (such as pituitary adenoma in some classifications) are categorised separately.
Most published Alpha PRRT protocols use 3 to 4 cycles spaced 8 to 12 weeks apart. Dosing is typically 100 kBq per kilogram body weight per cycle.
Decisions to continue, pause or switch are response-driven, guided by interim 68Ga-DOTATATE PET imaging, biomarker trends (chromogranin A), and clinical symptom assessment.
Alpha PRRT side effects overlap with conventional Lu-DOTATATE PRRT but with some differences. Common: mild fatigue, mild nausea, transient cytopenias. Specific to alpha: more pronounced bone-marrow suppression and slightly greater renal stress than beta PRRT.
Xerostomia (dry mouth) is less prominent than with Alpha PSMA therapy because SSTR-2 expression in salivary glands is much lower than PSMA expression. Severe toxicity is rare with appropriate dosimetry and amino acid renal protection.
At Theranostic Physicians, Alpha PRRT (Ac-225 DOTATATE) is priced per cycle based on the calculated patient dose. Indicative range: approximately ₹ 13,00,000 to ₹ 16,00,000 per cycle for Indian patients; USD 15,000 to USD 18,000 per cycle for international patients.
Course pricing for a typical 3 to 4 cycle protocol totals ₹ 40 to 60 lakh. A formal written quote follows pre-treatment evaluation including 68Ga-DOTATATE PET review and dosimetry planning.
Written & Medically Reviewed By
Dr. Ishita B. Sen
MBBS · DRM · DNB (Nuclear Medicine) · 30+ years in nuclear oncology
Senior Director and Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute. She completed a Visiting Fellowship at Memorial Sloan Kettering Cancer Center, New York, and a thyroid cancer preceptorship at the University of Marburg, Germany. Past President, Association of Nuclear Medicine Physicians of India. Active interest in alpha radioligand therapies including Ac-225 PRRT and Ac-225 PSMA protocols.
FellowshipsMSK New York · Marburg
Past PresidentANMPI
SpecialityAlpha theranostics for NETs
Full profile
References & citations
- Kratochwil C, Giesel FL, Bruchertseifer F, et al. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumors refractory to beta radiation: a first-in-human experience. European Journal of Nuclear Medicine and Molecular Imaging, 2014;41(11):2106–19. — Heidelberg proof-of-concept.
- Ballal S, Yadav MP, Bal C, et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT. European Journal of Nuclear Medicine and Molecular Imaging, 2020;47(4):934–946. — AIIMS Delhi single-centre series.
- Demir B, Wadhwa V, Yadav S, et al. Ac-225 DOTATATE in metastatic neuroendocrine tumors: outcomes of a Turkish multicentre experience. Annals of Nuclear Medicine, 2022;36(11):965–975.
- Sathekge M, Bruchertseifer F, Vorster M, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019;46(1):129–138. — Pretoria alpha experience methodology.
- Yadav MP, Ballal S, Sahoo RK, Bal C. Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: A pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2022;49(5):1595–1606. — AIIMS paraganglioma cohort.
- Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017;376(2):125–135. — NETTER-1, benchmark beta PRRT trial referenced for Lu vs Ac comparison.